Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON
  1. Accueil Zonebourse
  2. Actions
  3. Australie
  4. Australian Stock Exchange
  5. Immutep Limited
  6. Actualités
  7. Autres langues
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Rapport
SynthèseGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur IMMUTEP LIMITED
26/11IMMUTEP : Results of Annual General Meeting
26/11IMMUTEP : AGM 2021 - CEO's presentation
26/11IMMUTEP : AGM 2021 - Chairman's Address
22/11IMMUTEP : Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy..
22/11IMMUTEP : Goetzpartners securities -Data highlights efti efficacy and potential central ro..
19/11Immutep Completes Recruitment for Phase 2 Study of Therapy Candidate for Several Types ..
19/11Immutep Completes Recruitment for Phase 2 Cancer Trial
19/11IMMUTEP : Phase II TACTI-002-002 trial recruitment successfully completed
18/11Immutep Limited Announces the Enrollment of Last Patient in the Expansion Stage of Part..
18/11IMMUTEP : Maxim Group - AIPAC Presentation at SITC Builds on Prior Data, Prepping to Go Pi..
18/11IMMUTEP : Wilsons Equity Research - Immutep Limited (IMM) | Efti impresses in HNSCC and ai..
15/11IMMUTEP : Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New..
15/11Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, i..
15/11Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive Ne..
15/11Immutep Secures Chinese Patent for Immunotherapy Drug Candidate
15/11IMMUTEP : Chinese patent Granted for Efti with PD-1 Pathway Inhibitors
14/11IMMUTEP : announces publication of SITC 2021 posters
14/11Immutep Limited Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters At SITC with Pos..
12/11Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive Ne..
12/11SITC 2021 - AIPAC Poster
12/11SITC 2021 - TACTI-003 Poster
12/11SITC 2021 - TACTI-002 Poster
12/11Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021..
12/11AIPAC FINAL DATA AS EXPECTED : Phase III supported with maintaining a Buy Rating (ASX:IMM)..
09/11Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021..
09/11TACTI-003 : A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizuma..
09/11Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembroli..
09/11Late Breaking Abstract for SITC 2021 - AIPAC
09/11Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key P..
09/11Immutep Limited Reports Improved and Statistically Significant Survival Benefit for Thr..
04/11O/W : IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Me..
03/11IMMUTEP GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBI..
02/11Immutep Secures Chinese Patent for Anti-Cancer Lead Product Candidate
02/11Immutep granted chinese patent for eftilagimod alpha, a soluble lag-3 protein, in combi..
29/10Immutep Receives Positive Feedback From European Medicines Agency About Efti to Treat B..
29/10Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Eft..
29/10Immutep Limited Receives Positive EMA Scientific Advice for Further Clinical Developmen..
29/10Immutep receives positive EMA scientific advice for further clinical development of eft..
29/10Immutep Receives Scientific Advice for Clinical Development of Cancer Drug
29/10Immutep receives EMA scientific advice in Phase 3 in MBC
28/10Immutep Limited Receives EMA Scientific Advice for Phase 3 in MBC
28/10Immutep Quarterly Activities Report & Appendix 4C - Form 6-K
28/10Immutep Limited Provides an Update on the Ongoing Development of its Product Candidate
28/10Immutep Quarterly Activities Report & Appendix 4C
13/10IMMUTEP : Corporate Connect - A Truly Undervalued Company
12/10IMMUTEP : 2021 Annual General Meeting and Key Dates
04/10IMMUTEP : to Present Data, Trial Design of Clinical Studies for Cancer Treatments During M..
04/10IMMUTEP : to present Phase II TACTI-002 data at SITC 2021
01/10IMMUTEP : to Present Phase II TACTI-002 Data at SITC 2021
29/09IMMUTEP : Receives $2.49 Million as R&D Tax Incentive from French Government
29/09IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government
29/09IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government (Form 6-K)
29/09IMMUTEP : Receives $2.5 Million Tax Incentive from France
29/09IMMUTEP : Receives A$3.4 million R&D French Tax Incentive
28/09IMMUTEP : to Present at Healthcare Investor Conferences
21/09Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking ..
21/09Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking ..
20/09IMMUTEP : Maxim Group - The Case for LAG-3 is Building
20/09IMMUTEP : ESMO 2021 – INSIGHT - Stratum D Poster
20/09IMMUTEP LIMITED(NASDAQGM : IMMP) added to S&P Global BMI Index
02/09IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-..
01/09IMMUTEP : Completes Patient Enrollment in Stage 2 of Part B of NSCLC Study; Shares Drop Ea..
01/09IMMUTEP : PRELIMINARY FINAL REPORT (Form 6-K)
01/09IMMUTEP : Completes Recruitment, Dosing in Phase 2 Trial of Non-Small Cell Lung Cancer Com..
01/09IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-..
01/09Immutep Limited Announces Recruitment of Patients Completed for Part B of TACTI-002
31/08IMMUTEP : Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
31/08IMMUTEP : Chinese Partner to Expand Clinical Trial Pipeline for Cancer Drug
31/08IMMUTEP : S CHINESE PARTNER, EOC PHARMA, EXPANDS EFTI TRIAL PIPELINE (Form 6-K)
31/08IMMUTEP : Partner, EOC Pharma, Expands Efti Trial Pipeline
30/08IMMUTEP : Maxim Group - Annual FY Update; AIPAC Final Data Approaching
30/08Immutep Limited Reports Earnings Results for the Full Year Ended June 30, 2021
27/08ADRs End Higher, Immutep and BioNTech Among Companies Actively Trading
27/08IMMUTEP : ANNOUNCES CHINESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 (Form 6-K)
27/08IMMUTEP : Receives Chinese Patent for LAG-3 Antagonist Antibody LAG525
1  2  3  4  5  6  7  8Suiv.